Log In Sign up
The largest database of trusted experimental protocols

Anti menin a300 105a

Manufactured by Fortis Life Sciences
Visit Supplier
Sourced in United Kingdom

The Anti-Menin (A300-105A) is a laboratory reagent produced by Fortis Life Sciences. It is a protein-specific antibody that is designed to detect and bind to the Menin protein. Menin is a nuclear protein that plays a role in various cellular processes. The Anti-Menin (A300-105A) can be used in research applications that involve the study of Menin and its interactions.

Automatically generated - may contain errors

Lab products found in correlation

Anti h3k4me3 ab8580, by Abcam (1 mentions) Anti h3k27me3 ab6002, by Abcam (1 mentions) Pgex 6p 1, by Addgene (1 mentions) Fulvestrant ici, by Merck Group (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Mi 503, by Selleck Chemicals (1 mentions) Anti β actin a1978, by Merck Group (1 mentions) Epz004777, by Selleck Chemicals (1 mentions) Anti dot1l a300 953a, by Fortis Life Sciences (1 mentions) Rabbit igg isotype control 31 235, by Thermo Fisher Scientific (1 mentions) Pinometostat epz5676, by Selleck Chemicals (1 mentions) 4 hydroxytamoxifen tam, by Merck Group (1 mentions) Anti flag a8592, by Merck Group (1 mentions)

Spelling variants of this product

Anti-Menin (8 citations) Menin (3 citations)

3 protocols using anti menin a300 105a

1

Plasmid and Antibody Usage Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following plasmids have been used in this study: pCDH-EF1-MSCV-GFP-Puro (SBI, CD711B-1) and pGEX-6P-1 (Addgene). Antibodies: mouse and rabbit immunoglobulin G (IgG) (sc-69786 and sc-66931) were from Santa Cruz Biotechnology. anti-PTIP (A300-369A and A300-370A), anti-PA1 (A301-978A and A301-979A), anti-Menin (A300-105A), and anti-CXXC1 (A303-161A) were ordered from Bethyl Laboratories. anti-WDR5 (ab56919), anti-H3K4me3 (ab8580), and anti-H3K27me3 (ab6002) were from Abcam.
Xiao T., Liu L., Li H., Sun Y., Luo H., Li T., Wang S., Dalton S., Zhao R.C, & Chen R. (2015). Long Noncoding RNA ADINR Regulates Adipogenesis by Transcriptionally Activating C/EBPα. Stem Cell Reports, 5(5), 856-865.
+ Open protocol
+ Expand
2

Investigating ERα, Dot1L, and Menin Interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
The antibodies used for co-immunoprecipitation and/or western blot analyses were the following: anti-ERα C-terminal (F-10 sc-8002, Santa Cruz Biotechnology, Dallas, Texas), anti-ERα (ab3575) and anti-KMT4/Dot1L (ab72454) from Abcam (Cambridge, UK), anti-Dot1L (A300-953A), antimenin (A300–105 A) and anti-WSTF (BAZ1B; A300-446A) from Bethyl Laboratories (Montgomery, Alabama), anti-β-actin (A1978) from Sigma-Aldrich (Milan, Italy), Rabbit IgG Isotype Control (31,235) from Thermo Fisher (Milan, Italy). Compounds used for cell treatments were 4-hydroxytamoxifen (TAM; H7904, Sigma-Aldrich), fulvestrant (ICI; I4409, Sigma-Aldrich), 17β-estradiol (E887-5G, Sigma-Aldrich). Pharmacological inhibition was performed with EPZ004777 (S7353; only for RNA-seq experiments) and Pinometostat EPZ5676 (S7062; for all the other experiments included in the manuscript) for Dot1L and with MI-136 (S7815) and MI-503 (S7817) for menin, all purchased from Selleckchem (Houston, TX, USA). All inhibitors were dissolved in DMSO (Sigma-Aldrich), which was therefore used as a vehicle.
Salvati A., Melone V., Sellitto A., Rizzo F., Tarallo R., Nyman T.A., Giurato G., Nassa G, & Weisz A. (2022). Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer. Breast Cancer Research : BCR, 24, 52.
+ Open protocol
+ Expand
3

Antibody Production and Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Polyclonal anti-SET1A and anti-DPY30 antibodies were developed against purified histidine-tagged human SET1A fragment (amino acid residues 358–477) and human DPY-30 (full-length) proteins, respectively, and affinity purified (AbClon). Polyclonal anti-CFP1 and anti-WDR82 antibodies were obtained from the Roeder laboratory. Polyclonal anti-WDR5 antibody was obtained from the Allis laboratory. The following antibodies were obtained commercially: anti-SET1B (A302-281A), anti-MLL2 (A300-113A), anti-RbBP5 (A300-109A), anti-ASH2L (A300-489A), and anti-Menin (A300-105A) from Bethyl Laboratories; anti-WDR5 (ab22512), anti-H3 (ab1791), anti-H3K4me1 (ab8895), and anti-H3K4me2 (ab7766) from Abcam; anti-H3K4me3 (AM39159) from Active Motif; and anti-FLAG (A8592) from Sigma.
Kwon M., Park K., Hyun K., Lee J.H., Zhou L., Cho Y.W., Ge K., Skalnik D.G., Muir T.W, & Kim J. (2020). H2B ubiquitylation enhances H3K4 methylation activities of human KMT2 family complexes. Nucleic Acids Research, 48(10), 5442-5456.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!